Immunome IMNM Business Segments — Interest Income Expense Net

Similar metrics at other companies

EWTXSingle Reportable — Interest Income Expense Nonoperating Net

$5.1M-1.1%

VERXSingle Reportable — Interest Income Expense Net

-$957K+37.8%

ONTOSingle Reportable — Interest Income Expense Nonoperating Net

$8.74M+4.4%

NCLHSingle Reportable — Interest Income Expense Nonoperating Net

-$165.99M+23.8%

DGSingle Reportable — Interest Income Expense Nonoperating Net

-$47.24M+26.9%

APLEReportable — Interest Income Expense Net

-$20.07M-3.5%

Questions, answered.

What is Immunome's business segments — interest income expense net?

Immunome (IMNM) reported business segments — interest income expense net of $5.49M in Q1 2026.

How has Immunome's business segments — interest income expense net changed year-over-year?

Immunome's business segments — interest income expense net increased by 83.3% year-over-year, from $3M to $5.49M.

What is the long-term trend for Immunome's business segments — interest income expense net?

Over 2 years (2023 to 2025), Immunome's business segments — interest income expense net has grown at a 107.4% compound annual growth rate (CAGR), from $2.72M to $11.72M.

What does business segments — interest income expense net mean?

The net result of interest income earned on cash and investments minus interest expenses incurred on debt or other financial obligations. This metric reflects the company's treasury management and the cost of its capital structure. A positive value indicates the company is generating returns on its cash reserves, while a negative value indicates a cost of borrowing.